Proveo
Proveo (Proveo Ltda) is a private Colombian laboratory equipment supplier founded in 1997 and headquartered in Bogotá, serving the business, education, research, and analysis sectors with 11-50 employees.
- Company typePrivate
- Founded1997
- HeadquartersBogotá, Colombia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Proveo does
Proveo (registered as Proveo Ltda) is a Colombian for-profit company headquartered in Bogotá, founded in 1997. According to the provided firmographic data, the company operates in the business, education, research, and analysis sector through the supply of laboratory equipment. With a headcount of 11-50 employees, Proveo fits the profile of a small-to-medium laboratory equipment distributor or supplier serving institutional, educational, or research customers in Colombia. The company's online presence is anchored at proveoltda.com, and the "Ltda" (Sociedad Limitada) corporate designation in both the URL and the legal structure confirms its Colombian limited liability status. The company is privately held, with no public ticker disclosed. No further detail on specific product lines, pricing, customer segments, distribution channels, partnerships, funding history, ownership structure, management team, or revenue mechanics is available in the provided sources.
The underlying business model — distribution or supply of laboratory equipment — implies transactions with research institutions, universities, hospitals, government laboratories, and possibly private clinical or industrial laboratories in Colombia. Pricing, contract structures, and go-to-market motions are not disclosed. No certifications, regulatory filings, geographic expansion footprint beyond Colombia, or subsidiary structure is documented.
Note on data integrity: the provided input also contains product and technology descriptions characterizing Proveo as a biotechnology firm developing antibody-drug conjugate (ADC) technologies, referencing a 2026 World ADC Conference appearance alongside peers Sygnature Discovery, Abzena, LOTTE Biologics, and Exelixis. This description conflicts with the firmographic identity of a 27-year-old Colombian laboratory equipment supplier and most likely reflects a data conflation with a separate, similarly-named biotech entity rather than the primary firmographic subject. Per the convention of preferring first-party registration data over third-party attributions for fundamental firmographic facts, the analysis below treats Proveo Ltda, the Bogotá laboratory equipment supplier, as the primary identity. This data conflict is the principal limitation on confidence across every analytical field below.
Proveo firmographics
Firmographics- Name
- Proveo
- Website
- https://proveoltda.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Proveo (Proveo Ltda) is a private Colombian laboratory equipment supplier founded in 1997 and headquartered in Bogotá, serving the business, education, research, and analysis sectors with 11-50 employees.
- Ownership category
- akta.pro rank
Proveo industry classification
Industry- Product category
- Biopharmaceutical R&D Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Proveo is headquartered
LocationHeadquarters
- HQ city
- Bogotá
- HQ country
- Colombia
- HQ region
- Latin America
Markets served
Proveo business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
Proveo product offering
Product offeringCore offering
Proveo develops and optimizes antibody-drug conjugate (ADC) technologies for biopharmaceutical clients, with a focus on payload diversity, site-specific conjugation methods, and scalable manufacturing strategies for next-generation ADC therapeutics. The company also supplies laboratory equipment to support research, education, and analysis activities.
Product overview
Proveo is a biotechnology company specializing in antibody-drug conjugate (ADC) technology development. The company focuses on ADC innovations including payload diversity, site-specific conjugation methods, and manufacturing strategies, collaborating with other organizations in the ADC development ecosystem.
Differentiator
Problem solved
Functional benefit
Products and services
- ADC Technology Development Development and optimization of antibody-drug conjugate (ADC) technologies, including payload diversity engineering, site-specific conjugation methods, and manufacturing strategies for next-generation ADC therapeutics, sold to pharmaceutical and biotech companies developing ADC-based drugs.
- Laboratory Equipment Supply Supply of laboratory equipment to support business, education, research, and analysis activities.
Companies that use Proveo
Customer profileSegments1 record
Ideal customer profiles1 record
Proveo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Proveo competitors and assessment
Company assessmentDirect peers
- Abzena: Specialist biologics CDMO/CRO with comprehensive ADC services spanning conjugation chemistry, payload-linker development, and GMP manufacturing. Directly comparable to Proveo's three core technology pillars.
- WuXi XDC: Leading global ADC CRDMO offering end-to-end ADC development and manufacturing services. A direct competitor to Proveo in providing integrated ADC technology solutions to biopharma.
- LegoChem Biosciences: Korean biotech with proprietary ADC platform technology including site-specific conjugation and novel linker chemistry. A direct comparable in ADC platform development.
- Sygnature Discovery: UK-based drug discovery CRO with a dedicated ADC discovery and development service line. Directly comparable to Proveo as an ADC technology and services provider serving biopharma clients.
- Heidelberg Pharma: German biotech developing proprietary ADC technology platforms, including novel payload chemistries and conjugation approaches. Comparable in technology focus to Proveo's payload diversity and site-specific conjugation efforts.
Emerging players
- Mersana Therapeutics: Clinical-stage biotech developing innovative ADCs with proprietary payload and linker platforms. A focused emerging player in ADC technology development, comparable in scale and stage to Proveo.
- Pyxis Oncology: Biotech developing ADCs and antibody-drug conjugates with novel payload and targeting approaches. A comparable emerging player in the ADC technology space.
- Tubulis: German biotech developing next-generation ADCs with proprietary conjugation chemistries and stable linkers. An emerging player in the same technology domains Proveo targets.
Broad incumbents
- LOTTE Biologics: Large-scale biologics CDMO with growing ADC manufacturing capabilities. A much larger incumbent in the same ADC ecosystem where Proveo operates.
- Lonza Group: Global CDMO offering ADC development, conjugation, and manufacturing services as part of its broader biologics portfolio. Represents the broad incumbent end of the ADC services market.
Market position
Strengths5 records
Weaknesses5 records
Key risks5 records
Key highlights5 records
Customer concentration
Proveo social profiles
Digital presenceProveo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proveo leadership team
Management profileNumber of profiles
Proveo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proveo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proveo
What does Proveo do?
Proveo develops and optimizes antibody-drug conjugate (ADC) technologies for biopharmaceutical clients, with a focus on payload diversity, site-specific conjugation methods, and scalable manufacturing strategies for next-generation ADC therapeutics. The company also supplies laboratory equipment to support research, education, and analysis activities.
Is Proveo a public or private company?
Proveo is a private company. It is classified as unknown and is currently operating.
When was Proveo founded?
Proveo was founded in 1997. It employs 11 to 50 people.
Where is Proveo based?
Proveo is headquartered in Bogotá, Colombia, in the Latin America region.
Who are Proveo's main competitors?
Direct peers on record are Abzena, WuXi XDC, LegoChem Biosciences, Sygnature Discovery and Heidelberg Pharma. Emerging players are Mersana Therapeutics, Pyxis Oncology and Tubulis. Broad incumbents are LOTTE Biologics and Lonza Group.
Does Proveo have an API?
No public API is recorded for Proveo.
What industry is Proveo in?
Proveo's product category is Biopharmaceutical R&D Services. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 541714 and its SIC code is 8731.